Noradrenalina Noridem (Noradrenaline Tartrate)

Noradrenaline binds directly to alpha‑adrenergic receptors on vascular smooth muscle, causing strong vasoconstriction and increasing systemic vascular resistance. It also stimulates beta‑1 receptors in the heart, modestly enhancing contractility and cardiac output, together supporting blood pressure and organ perfusion during shock.

The specific dose is determined by the prescribing clinician based on the patient’s haemodynamic status. Typically, the drug is administered as a continuous intravenous infusion that is titrated to achieve a target mean arterial pressure, with dosing adjustments made according to continuous monitoring.

Safety data for noradrenaline in pregnancy and lactation are limited. It should only be used when the potential maternal benefit outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Noradrenaline is often preferred over agents such as dopamine or phenylephrine because it provides balanced alpha‑mediated vasoconstriction with modest beta‑1 activity, leading to more predictable blood pressure control and less tachyarrhythmia risk. Choice of vasopressor depends on the clinical scenario and physician judgment.

The product must be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Prior to use, allow the vial to reach room temperature if required, and inspect for particulate matter before administration.

Noradrenalina Noridem is given by intravenous infusion, usually through a central or large peripheral vein. The infusion is started at a low rate and titrated based on continuous blood pressure monitoring to achieve the desired haemodynamic target.

Serious risks include severe hypertension, life‑threatening cardiac arrhythmias, myocardial ischemia, and peripheral tissue necrosis due to intense vasoconstriction. Prompt recognition and immediate adjustment of the infusion rate are essential to mitigate these complications.

Contraindications include patients with known hypersensitivity to noradrenaline or its excipients, uncorrected tachyarrhythmias, and severe peripheral vascular disease where further vasoconstriction could cause tissue loss. Use in these populations should be avoided or undertaken with extreme caution.